DE60143799D1 - Genetisch hergestellte mhc moleküle - Google Patents

Genetisch hergestellte mhc moleküle

Info

Publication number
DE60143799D1
DE60143799D1 DE60143799T DE60143799T DE60143799D1 DE 60143799 D1 DE60143799 D1 DE 60143799D1 DE 60143799 T DE60143799 T DE 60143799T DE 60143799 T DE60143799 T DE 60143799T DE 60143799 D1 DE60143799 D1 DE 60143799D1
Authority
DE
Germany
Prior art keywords
component
cells
polypeptide
class
zeta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60143799T
Other languages
English (en)
Inventor
Gideon Gross
Alon Margalit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gavish-Galilee Bio Applications Ltd
Original Assignee
Gavish-Galilee Bio Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gavish-Galilee Bio Applications Ltd filed Critical Gavish-Galilee Bio Applications Ltd
Application granted granted Critical
Publication of DE60143799D1 publication Critical patent/DE60143799D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE60143799T 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle Expired - Lifetime DE60143799D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13651100A IL136511A0 (en) 2000-06-01 2000-06-01 Genetically engineered mhc molecules
PCT/IL2001/000506 WO2001091698A2 (en) 2000-06-01 2001-05-31 Genetically-engineered mhc molecules

Publications (1)

Publication Number Publication Date
DE60143799D1 true DE60143799D1 (de) 2011-02-17

Family

ID=11074209

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60143799T Expired - Lifetime DE60143799D1 (de) 2000-06-01 2001-05-31 Genetisch hergestellte mhc moleküle

Country Status (7)

Country Link
US (1) US7319143B2 (de)
EP (1) EP1301202B1 (de)
AT (1) ATE494004T1 (de)
AU (1) AU7443901A (de)
DE (1) DE60143799D1 (de)
IL (2) IL136511A0 (de)
WO (1) WO2001091698A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507550A1 (de) * 2002-05-30 2005-02-23 Sloan Kettering Institute For Cancer Research Suizid-tetramere mit mhc klasse i und ihre verwendungen
WO2003106616A2 (en) * 2002-06-12 2003-12-24 Gavish-Galilee Bio Applications Ltd MEMBRANE-ANCHORED β2 MICROGLOBULIN COVALENTLY LINKED TO MHC CLASS I PEPTIDE EPITOPES
WO2006077152A2 (en) * 2005-01-21 2006-07-27 Utku Nalan Hla fusion molecules and uses thereof
BR122021026169B1 (pt) 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania Uso de uma célula
WO2012127464A2 (en) 2011-03-23 2012-09-27 Gavish-Galilee Bio Applications Ltd Constitutively activated t cells for use in adoptive cell therapy
RU2708032C2 (ru) 2013-02-20 2019-12-03 Новартис Аг ЛЕЧЕНИЕ РАКА С ИСПОЛЬЗОВАНИЕМ ХИМЕРНОГО АНТИГЕНСПЕЦИФИЧЕСКОГО РЕЦЕПТОРА НА ОСНОВЕ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ EGFRvIII
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP2970426B1 (de) 2013-03-15 2019-08-28 Michael C. Milone Anzielung zytotoxischer zellen mit chimären rezeptoren für eine adoptive immuntherapie
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (de) 2013-12-20 2024-06-05 Novartis AG Regulierbarer chimärer antigenrezeptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
AR101829A1 (es) 2014-07-21 2017-01-18 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
PL3183268T3 (pl) 2014-08-19 2020-09-07 Novartis Ag Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP4056588A1 (de) 2015-04-08 2022-09-14 Novartis AG Cd20-therapien, cd22-therapien und kombinationstherapien mit einer zelle zur expression des chimären antigen-rezeptors (car) cd19
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
RU2019133280A (ru) 2017-03-22 2021-04-22 Новартис Аг Композиции и способы для иммуноонкологии
US20190201443A1 (en) * 2017-09-06 2019-07-04 California Institute Of Technology Signaling and antigen-presenting bifunctional receptors (sabr)
KR20200086278A (ko) 2017-10-18 2020-07-16 노파르티스 아게 선택적 단백질 분해를 위한 조성물 및 방법
EP3784696A1 (de) * 2018-04-23 2021-03-03 Baylor College Of Medicine Chimärer akzessorischer hla-rezeptor
KR20210005923A (ko) * 2018-04-27 2021-01-15 크리스퍼 테라퓨틱스 아게 세포독성 t 세포 고갈의 방법 및 조성물
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
WO2020097188A1 (en) * 2018-11-06 2020-05-14 Sangamo Therapeutics, Inc. Identification of molecules for inhibition of nk-mediated cell killing
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69123241T2 (de) * 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
WO1997008328A1 (en) * 1995-08-30 1997-03-06 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Selective elimination of t cells that recognize specific preselected targets
DE19545351C1 (de) * 1995-12-05 1997-07-31 Univ Ludwigs Albert Eukaryotische Zellen mit Hybridrezeptor und dadurch steuerbarem Genkonstrukt, Verfahren zu deren Herstellung und Verwendung dieser Zellen in der Gentherapie

Also Published As

Publication number Publication date
WO2001091698A2 (en) 2001-12-06
WO2001091698A3 (en) 2002-04-11
US20040137562A1 (en) 2004-07-15
US7319143B2 (en) 2008-01-15
AU7443901A (en) 2001-12-11
IL136511A0 (en) 2001-06-14
EP1301202A4 (de) 2005-01-05
EP1301202B1 (de) 2011-01-05
IL153091A (en) 2011-01-31
ATE494004T1 (de) 2011-01-15
EP1301202A2 (de) 2003-04-16

Similar Documents

Publication Publication Date Title
DE60143799D1 (de) Genetisch hergestellte mhc moleküle
Baier et al. Molecular cloning, sequence, expression, and processing of the interleukin 16 precursor
Cantoni et al. p49, a putative HLA class I‐specific inhibitory NK receptor belonging to the immunoglobulin superfamily
AU6063500A (en) Glycoprotein vi and uses thereof
DK0726952T3 (da) Receptor benævnt ACT-4 på overfladen af aktiverede T-celler
DE69528894T2 (de) Bifunktionelles protein, herstellung und verwendung
HK1203975A1 (en) Genetically modified human natural killer cell lines
Jabri et al. Human CD8+ intraepithelial lymphocytes: a unique model to study the regulation of effector cytotoxic T lymphocytes in tissue
ATE440951T1 (de) Verlängerte cdns, die für sekretierte proteine kodieren
DK1210430T3 (da) MUC-1-afledte peptider
MXPA03002971A (es) Receptores de hematopoyetina hpr1 y hpr2.
WO1995023859A3 (en) Novel forms of t cells costimulatory molecules and uses therefor
Ungefroren et al. Immunological escape mechanisms in pancreatic carcinoma
ATE243253T1 (de) Rezeptoren der wachstumsfaktoren aus fibroblasten
HUP0301693A2 (hu) Antitest citokin-citokin inhibitorból (szelektokin) álló fúziós protein célspecifikus prodrugként történő alkalmazásra
DE69726674T2 (de) Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren
ES2152313T3 (es) Gen grb-3-3, sus variantes y sus utilizaciones.
Sharma et al. NKG2D signaling between human NK cells enhances TACE-mediated TNF-α release
Gould Dinosaurs in the haystack.
ATE177783T1 (de) Ein menschlicher t-zell rezeptor der protein g- gekoppelte rezeptor familie
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DK0781344T3 (da) Hidtil ukendt implantat og hidtil ukendt vektor til behandling af erhvervede sygdomme
Bosco et al. TCR‐β chains derived from peripheral γδ T cells can take part in αβ T‐cell development
Childs Isolation of members of the porcine P-glycoprotein multigene family (Sus domesticus)
Eiji et al. Molecular definition of human {beta} 2-glycoprotein ({alpha} 2-GPI) by cDNA cloning and inter-species differences of {beta} 2-GPI in alternation of anticardiolipin binding